Data as of Nov 20
| +0.37 / +8.31%|
Trovagene, Inc. is a development stage molecular diagnostic company that focuses on the development and commercialization of proprietary, in-vitro diagnostic technologies for use in patient/disease screening and monitoring across a variety of medical disciplines. Its primary internal focus is to leverage its novel urine-based molecular diagnostic platform to facilitate improvements in field of oncology, while its external focus includes developing collaborations in the areas of infectious disease, transplant medicine and prenatal diagnostics. The company's proprietary urine-based molecular diagnostic tests are designed to detect specific nucleic acids in urine which are known as transrenal DNA and RNA. It's technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. Trovagene was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
|Antonius P. Schuh||Chief Executive Officer & Director|
|Stephen L. Zaniboni||Chief Financial Officer|
|Charlie Rodi||Chief Technology Officer & Vice President|
|Mark Erlander||Chief Scientific Officer|
|B. Keith McCormick||Vice President-Commercial Operations|